Limited studies indicate increased free fraction of valproic acid in uremia. One study also described displacement of valproic acid from protein binding by salicylate in children with epilepsy. The authors studied in vitro interaction of valproic acid and salicylate in uremic sera and compared their results with same interactions in normal sera. As expected, the concentrations of free valproic acid were always significantly higher in uremic sera compared with normal sera. When uremic sera were supplemented with both valproic acid and salicylate, a much lower displacement of valproic acid by salicylate was observed, compared with the effects observed in normal sera. Treatment of uremic sera with charcoal removed those uremic compounds, and the concentration of free valproic acid in charcoal-treated uremic sera were comparable to the concentrations observed in normal sera. When uremic comValproic acid is a branched chain carboxylic acid that has become a first line antiepileptic drug.
Limited studies indicate increased free fraction of valproic acid in uremia. One study also described displacement of valproic acid from protein binding by salicylate in children with epilepsy. The authors studied in vitro interaction of valproic acid and salicylate in uremic sera and compared their results with same interactions in normal sera. As expected, the concentrations of free valproic acid were always significantly higher in uremic sera compared with normal sera. When uremic sera were supplemented with both valproic acid and salicylate, a much lower displacement of valproic acid by salicylate was observed, compared with the effects observed in normal sera. Treatment of uremic sera with charcoal removed those uremic compounds, and the concentration of free valproic acid in charcoal-treated uremic sera were comparable to the concentrations observed in normal sera. When uremic comValproic acid is a branched chain carboxylic acid that has become a first line antiepileptic drug. 1 Valproic acid is highly bound to serum albumin, and this binding within the therapeutic range is concentration dependent. 23 Inherent difficulties exist in monitoring clinical toxicity and therapeutic efficacy of highly protein bound drugs. 4, 5 The recent development in measuring the concentrations of free drug by combining the ultrafiltration technique to prepare a protein-free filtrate of serum and immunoassays to measure drug concentrations in the ultrafiltrate has facilitated the measurement of the pharmacologically active drug fraction. 6 Fraction of free valproic acid may range from 5.4% at the lower therapeutic level and may rise to 38.7% with increased total concentrations because of saturation in binding sites in albumin. 7 Valproic acid is therefore considered one of the special drugs for which monitoring of free drug concentrations is clinically useful. 8, 9 A recent study has demonstrated that the concentrations of free valproic acid have clinical significance in management of seizures, as well as pounds were extracted from charcoal with methanol, lyophilized, and added to normal serum, an increase in free valproic acid concentration in normal serum was observed, indicating that uremic compounds, rather than altering albumin structure, are responsible for elevated free valproic acid concentration in uremia. However, uremic extract failed to produce any further displacement of valproic acid in normal serum in the presence of salicylate. The authors concluded that uremic compounds are responsible for elevated free valproic acid concentrations, but the displacement of valproic acid by salicylate in uremic sera are less remarkable compared with such effect in normal sera. (Key words: Free valproic acid; Salicylate; Uremia) Am J Clin Pathol 1994; 101: 349-353. undesirable side effects, and recommended using free valproic acid concentrations in clinical management of patients. 10 Several studies had documented the lower protein-binding of phenytoin in uremia due to hypoalbuminemia, structural modification of albumin, and accumulation of uremic compounds in the blood that may displace phenytoin from protein binding."" 13 However, the protein binding of valproic acid in uremia had been poorly studied in the past, with no data available on the possibility of correcting such a binding defect by treatment of uremic sera with activated charcoal.
14 Moreover, limited data also indicate displacement of protein-bound valproic acid by salicylate in children with epilepsy." Because both uremic compounds and salicylate, a common over-thecounter drug, can displace valproic acid from protein-binding, we studied the in vitro interactions of valproic acid and salicylate in uremic sera and compared our results with those observed in the normal sera. We expected a synergistic effect of both uremic compounds and salicylate in displacing valproic acid in uremic sera, resulting in a high concentration of free drug. Instead, we observed a significantly reduced displacement of valproic acid in the presence of salicylate in uremic sera. We report this unexpected in vitro valproic acid-salicylate interaction in uremic sera, which has not been studied before.
MATERIALS A N D METHODS
Blood samples from uremic patients not on valproic acid, other commonly monitored therapeutic drugs, or salicylate 350 CLINICAL CHEMISTRY were collected before a routine dialysis session. The blood samples collected from these patients without any anticoagulant are submitted once a month to our clinical laboratory for routine analysis. The blood samples from normal volunteers were also collected without any anticoagulant. We separated the serum from the blood cells by centrifugation. Valproic acid and salicylic acid were purchased from Sigma Chemical Company (St. Louis, Mo).
A stock solution of valproic acid in methanol (4.5 mg/mL; 31.1 mmol/L) was prepared. The stock solution of salicylic acid (30 mg/mL; 2.2 mol/L) was prepared in .9% saline. Then, 1 mL aliquots of appropriate uremic and normal serum pools (diluted with .9% saline to mimic albumin concentrations of the corresponding uremic pools) were supplemented with 10-15 tiL of valproic acid stock solution to achieve desired concentrations of valproic acid in different experiments. Similarly, desired salicylate concentrations were achieved by supplementing those appropriate aliquots with 5-20 nL salicylate stock solutions. The samples were vortexed 1 minute each to achieve proper mixing and then incubated at 37°C for 3 hours in a temperature-controlled water bath. After incubation, the samples were allowed to equilibrate to room temperature for 10 minutes. The concentrations of total valproic acid were then measured by a fluorescence polarization immunoassay (Abbott Laboratories, Abbott Park, IL). For measuring the concentrations of free valproic acid, we prepared protein-free ultrafiltrate by centrifuging .5-.7 mL of sample in a Centrifree Micropartition System (Amicon, Danvers, MA) at 1162 X g for 20 minutes at 25°C. The concentration of valproic acid in the protein-free ultrafiltrate was then measured by another fluorescence polarization assay designed for free valproic acid (Abbott Laboratories). All free and total valproic acid concentrations were reported as the mean and standard deviation based on three replicates. The concentrations of total salicylic acid in sera were measured by a colorimetric assay using a Hitachi 704 analyzer (Boehringer Mannheim Corp., Indianapolis, IN). The assay was based on the reaction of salicylate with ferric nitrate in an acid medium to form an iron complex with a violet color. The assay is an end-point type, and the intensity of color was measured at 546 nm. The concentrations of albumin, creatinine, and urea in sera were measured by a Hitachi 747 analyzer and reagents provided by Boehringer Mannheim Corp.
The charcoal treatment experiments were performed according to Chen. 16 For such experiments, pH of the sera was adjusted to 3 with 2 N hydrochloric acid followed by addition of activated charcoal (50 mg for each mL of serum) and mechanical mixing for 1 hour at 4°C in a cold room. After removal of charcoal by centrifugation, the serum pH was adjusted to 7.4 with 2 N sodium hydroxide. The albumin concentrations in the original (both uremic and normal pool) and charcoal-treated sera were then measured. The lowest albumin concentration of 34 g/L was observed in the charcoaltreated uremic serum pool. The concentration of albumin in all sera were adjusted to 34 g/L before supplementing with valproic acid and salicylate for further experiment. The uremic compounds absorbed in activated charcoal were extracted back by methanol. Then methanol extracts were evaporated to dryness, and the solid residues were added to the appropriate aliquots of the normal sera for further experiments.
The statistical analysis was done by using independent Mest. We considered the differences statistically significant only at 95% confidence interval using two-tailed test.
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• Article Values are mean of three replicates ± SD. * Albumin concentrations of all sera were adjusted to 35 g/L for pool A, 32 g/L for pool B, and 37 g/L for pool C.
t Significantly different from free valproic acid concentrations in uremic sera in absence of salicylate.
X Significantly different from free valproic acid concentration in uremic serum in presence of 2.3 mmol/L salicylate.
RESULTS
The sera collected for this study were free from any commonly monitored therapeutic drugs or salicylate. Our initial experiments with predialysis sera from two patients and control sera from normal volunteers supplemented with valproic acid and salicylate indicated much lower displacement of valproic acid by salicylate in uremic sera. In one set of experiments, for example, the concentration of free valproic acid was increased from 119.4 jtmol/L to 153.1 jitmol/L in the presence of 1.5 mmol/L of salicylate in uremic serum. In normal serum, however, the concentrations of valproic acid increased from 59 /umol/L to 167.3 /xmol/L in the presence of 1.5 mmol/L of salicylate. Both uremic and normal sera were supplemented with the same concentration of valproic acid (556.7 ^mol/L), and the albumin concentrations of the normal serum was adjusted to 35 g/L to mimic the albumin concentration of uremic serum.
To investigate this observation further, we prepared three serum pools from predialysis sera of uremic patients. Again, the concentrations of free valproic acid were always significantly higher in uremic sera compared with normal sera (adjusted to the same albumin concentrations as the uremic sera), although both sera were supplemented with the same concentration of valproic acid. In two of three sets of experiments, the concentrations of free valproic acid in the presence of salicylate were not significantly different; in one set, the concentrations were significantly lower in uremic sera compared with normal sera. In experiment 3 (Table 1) , the concentration of valproic acid in uremic (x = 467.8, standard deviation [SD] = 15.3 fimo\/L) and normal sera (x = 483.7, SD = 7.6 jtmol/L) were not statistically different. However, the mean free valproic acid concentrations in uremic serum (x = 239, SD=4.9 ^mol/L) was significantly higher than the normal serum {x = 201.6, SD = 2.1 jumol/L). The concentration of albumin in the normal serum was adjusted to 37 g/L to mimic uremic serum before Reduced In Vitro Displacement of Valproic Acid supplementing them with valproic acid and salicylate. When the same concentration of salicylate was added to uremic and normal sera already supplemented with valproic acid, the total concentrations of valproic acid were not significantly different as expected. However, the concentration of free valproic acid in the uremic serum (x=3\7.4, SD = 8.3 Mmol/L) in this case was significantly lower than the normal serum (x = 349.2, SD = 13.2 mmol/L).
In another set of experiments, when 1 mL aliquots of appropriate serum pools (three replicates) were supplemented with 307 ^mol/L valproic acid, the mean concentration of free valproic acid in uremic serum was 107.4 Mmol/L (SD = 4.9) and in normal serum 60.3 Mmol/L (SD = 4.9). Supplementing another aliquot of those sera with 2.5 mmol/L salicylate resulted in a mean free valproic acid concentration of 189.9 Mmol/L (SD = 5.5) in uremic serum and 203 jtmol/L (SD = 6.2) in normal serum. Interestingly, the concentrations of free valproic acid in uremic serum and normal serum in the presence of salicylate were not statistically different. The addition of dry uremic extract to normal serum resulted in a free valproic acid concentration of 90.8 Mmol/L (SD = 1.4), a value significantly higher than that observed in the normal serum. However, adding the same quantity of dry uremic extract to another aliquot of normal serum and then supplementing it with valproic acid and salicylate resulted in a mean free valproic acid concentration of 187.8 /umol/L (SD = 7), a value not statistically different from the concentration of 189.9 /umol/L observed in normal serum in the presence of salicylate alone. These results indicate that uremic extract can cause further displacement of valproic acid in normal serum, but not in the presence of salicylate.
Charcoal treatment of uremic sera corrected the binding defect of valproic acid, as evidenced by the mean free valproic acid concentration of 38.1 Mmol/L (total valproic acid concentration 307.7 /imol/L). Interestingly, the mean concentration of free valproic acid was also reduced to 40.1 Mmol/L in normal serum after charcoal treatment. The addition of salicylate resulted in a mean free valproic acid concentration of 137.9 Mmol/L in charcoal-treated uremic serum and 167.0 Mmol/L in charcoal treated normal serum. Adding uremic extract to both normal serum and charcoal-treated normal serum led to further displacement of valproic acid. However, such effect was again masked by salicylate (Table 2.) Because the ability of salicylate to mask displacement of valproic acid by uremic extract in normal serum is our key finding, we decided to perform further experiments to verify this effect. We treated more uremic sera with charcoal and then extracted those uremic compounds back into methanol for further experiments. We performed two sets of experiments. In both cases, the concentrations of free valproic acid were significantly increased in the presence of uremic extract, as expected. However, uremic extract did not cause any statistically significant increase in free valproic acid concentration in the presence of salicylate (Table 3) .
We also studied the effect of concentration of salicylate on the displacement of valproic acid in a uremic serum and a normal serum pool. The normal serum pool was diluted to achieve an albumin concentration of 37 g/L to mimic the albumin concentration in the uremic pool before supplementation with valproic acid and salicylate. The initial mean concentration of free valproic acid in uremic serum was 156.6 Mmol/L. In the presence of .84 mmol/L salicylate, the concentration was increased to only 186.4 mmol/L (29.8 Mmol/L increment). However, the concentration of free valproic acid in normal serum was increased from 68.6 Mmol/L to 110.9 Mmol/L (42.3 Mmol/L increment) in the presence of .84 mmol/L salicylate. The effect of such displacement was even more remarkable in normal serum, with a higher concentration of salicylate compared with uremic serum (Fig. 1) .
DISCUSSION
Our data clearly indicate that the concentrations of free valproic acid were always higher in the uremic sera compared with Salicylate, mmol/L normal sera. Moreover, such effects were not related to hypoalbuminemia, which is commonly associated with uremia, because the concentrations of albumin in all normal sera were adjusted to mimic the albumin concentrations of uremic sera. The concentrations of free valproic acid also varied widely in uremic sera, even with comparable albumin concentrations. Therefore, prediction of free valproic acid concentrations, the pharmacologically active fraction in uremia based on total valproic acid and albumin concentrations, is difficult. Treatment of uremic sera with activated charcoal corrected the binding deficiency of valproic acid, a finding not reported before. However, several investigators have reported the correction of binding defect of phenytoin in uremic sera following treatment with activated charcoal. We also observed a statistically significant decrease in free valproic acid concentration in normal serum after treatment with activated charcoal. Therefore, some endogenous compounds are also present in normal sera, which may displace valproic acid from protein binding. Moreover, addition of dried uremic extract to normal serum and charcoal-treated normal serum caused significant increases in free valproic acid concentrations, indicating that uremic compounds, rather than altered albumin structure in uremic sera, are responsible for the increased free valproic acid concentrations. Because the amount of displacement of valproic acid in uremic sera cannot be predicted from any known parameter, such as albumin concentration, monitoring free valproic acid concentrations instead of total valproic acid concentration will be clinically more useful. Monitoring free phenytoin concentration in uremia has been recommended by several investigators.
Our results also clearly demonstrate significantly reduced displacement of valproic acid by salicylate in uremic sera compared with normal sera, a finding also not reported before. The concentrations of free valproic acid in uremic sera in the presence of 1.5-3 mmol/L salicylate were comparable to and in one case significantly lower than the concentrations of free valproic acid observed in normal sera. In the absence of salicylate, however, the concentrations of free valproic acid in uremic sera were in some cases 80% to 120% more than that of normal sera. The mechanism of such reduced interactions between salicylate and valproic acid currently is not clear. One possibility is an interaction between uremic compounds and salicylate, in which salicylate can displace uremic compounds from protein binding, thus reducing further displacement of valproic acid.
The addition of both uremic extract and salicylate to normal sera resulted in free valproic concentrations, which were not significantly different than concentrations obtained by adding salicylate alone. Such observations clearly indicate that the effects of uremic compounds and salicylate are not synergistic in displacing valproic acid from protein binding.
The dose-response study to investigate degree of displacement of valproic acid by salicylate also clearly indicates significantly reduced displacement in uremic serum compared with normal serum. At the lower end of the therapeutic range of salicylate, however, the concentration of free valproic acid in uremic serum was significantly greater than that observed with normal serum. Therefore, even a smaller magnitude of displacement of valproic acid by salicylate in uremic serum still leads to a higher concentration of free valproic acid. With 3 mmol/L salicylate, the concentrations of free valproic acid in uremic and normal sera were not different.
We conclude that free valproic acid concentrations are increased in uremia, and those concentrations may further increase in the presence of salicylate. However, the magnitude of displacement of valproic acid by salicylate in uremic sera is much less than that observed in normal sera. Because such an effect may also occur in vivo, monitoring free valproic acid concentrations in uremic patients will be useful. Moreover, even low dose salicylate may further increase the already elevated free valproic acid concentration in uremic patients. Caution should therefore be exercised for uremic patients who are receiving valproic acid and want to take salicylate.
